A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens
Completed
Duramed Research
Phase 3
2005-06-01
This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy,
reproductive-aged women using three different regimens of oral contraceptives (OCs). Two
extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days
followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg
for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia
(levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2005-08-01
The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE)
is effective in treating the symptoms of severe premenstrual syndrome (PMS).
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2005-09-01
The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE)
is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.
Human Ovarian Follicular Dynamics and Emergency Contraception
Completed
Canadian Institutes of Health Research (CIHR)
Phase 4
2005-07-01
The researchers hypothesize that emergency contraception (EC) will initiate the changes
associated with atresia or ovulatory failure at all stages of follicular development and that
the image attributes associated with atresia will be similar regardless of the diameter of
the dominant follicle when ovarian suppression is initiated. Second, changes associated with
atresia may be observed, but ovulation of the dominant follicle is unimpeded.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
